Rob Myers was named Chief Medical Officer of Mirum Pharmaceuticals, Inc., succeeding Joanne Quan. As of November 6, 2026, Mirum Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 8, 2026, naming 1 appointment and 1 departure (Form 8-K, September 8, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Mirum Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Mirum Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-08. It names 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Mirum Pharmaceuticals, Inc. files it.
Also on the record for Mirum Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 13, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP Ltd. | 9.7% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 6.2% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 5.7% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 11.8% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Eventide Asset Management, LLC | 4.1% of the class | 5%+ stakes | Source |
| January 29, 2026 | Form D, private offering | $68.48M sold | Form D page | Source |
| January 27, 2026 | Stake report, Schedule 13D/A, by Frazier Life Sciences IX, L.P. | 6.8% of the class | 5%+ stakes | Source |
| January 23, 2026 | Acquired Bluejay Therapeutics, Inc. | $280.80M | Acquisition | Source |
| December 5, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 10.6% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 10% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Mirum Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Mirum Pharmaceuticals, Inc. and the records around it.
Mirum Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Jan 2026
- Acquisition Jan 2026
- Who owns it
Companies that share a holder
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Immix Biopharma, Inc. (Aug 2026), Ovid Therapeutics Inc. (Aug 2026), Beta Bionics, Inc. (May 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
Watch Mirum Pharmaceuticals, Inc.
Get an email when Mirum Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Mirum Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Mirum Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mirum Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-08 | In | Chief Medical Officer | 8-K, 2026-09-08 | ||
| 2026-09-08 | Out | Chief Medical Officer | 2026-09-02 | 8-K, 2026-09-08 |
Who leads Mirum Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Rob Myers, appointed (filed 2026-09-08).
New leaders reset buying decisions — get the Full Report on Mirum Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Medical Officer at Mirum Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chief Medical Officer at Mirum Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: Rob Myers, Chief Medical Officer
On September 8, 2026, Mirum Pharmaceuticals, Inc. (the "Company") announced that, on September 2, 2026, the Company's Board of Directors appointed Rob Myers, M.D., to succeed Joanne Quan, M.D., as the Company's Chief Medical Officer, effective upon Dr. Myers' beginning employment with the Company, which employment is expected to begin on September 21, 2026.
Departing: Joanne Quan, Chief Medical Officer, effective 2026-09-02
Dr. Quan ceased to serve as the Company's Chief Medical Officer effective September 2, 2026, and her termination of employment with the Company is expected to occur on October 19, 2026 (the actual date of Dr. Quan's termination of employment, the "Separation Date").
- In connection with Dr. Quan's separation from the Company, the Company and Dr. Quan expect to enter into an agreement (the "Separation Agreement"), pursuant to which, in recognition of Dr. Quan's service to the Company, the Company expects Dr. Quan to be entitled to the severance benefits set forth in the Company's Amended and Restated Severance Benefit Plan as then in effect (the "Severance Plan"), subject to the terms and conditions set forth in the Severance Plan.
- In addition, on September 2, 2026, the Compensation Committee of the Company's Board of Directors approved (i) an extension of the post-termination exercise period for all vested and outstanding stock options granted by the Company and held by Dr. Quan on the Separation Date to a period expiring 12 months after the Separation Date and (ii) payment on the Separation Date of Dr. Quan's 2026 annual target bonus at the 100% achievement level.
- Receipt of the additional benefits described in the prior sentence are contingent upon Dr. Quan satisfying certain customary conditions to be set forth in the final Separation Agreement.
- Dr. Quan's separation from the Company is expected to qualify as an involuntary termination under the Severance Plan.
Tools for this story
Each opens in a new tab, filled in for Mirum Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.